Bridgefront Capital Buys Shares in Exact Sciences

Institutional investor adds 11,994 shares of medical research company to portfolio

Mar. 16, 2026 at 8:19am

Got story updates? Submit your updates here. ›

Bridgefront Capital LLC, an institutional investor, bought a new position in Exact Sciences Corporation (NASDAQ:EXAS) during the third quarter, acquiring 11,994 shares of the medical research company's stock valued at approximately $656,000, according to a recent SEC filing.

Why it matters

Exact Sciences is a prominent molecular diagnostics company known for its flagship product, the Cologuard colorectal cancer screening test. The company has expanded its portfolio through strategic acquisitions and internal R&D. Institutional investor activity in Exact Sciences shares can provide insights into market sentiment and the stock's performance outlook.

The details

According to the SEC filing, Bridgefront Capital LLC bought the 11,994 shares of Exact Sciences in the third quarter. Several other institutional investors have also recently made changes to their positions in EXAS, with Ameriprise Financial Inc., Massachusetts Financial Services Co. MA, and William Blair Investment Management LLC among the notable firms adjusting their stakes.

  • Bridgefront Capital LLC bought the 11,994 shares of Exact Sciences in the 3rd quarter.

The players

Bridgefront Capital LLC

An institutional investor that bought a new position in Exact Sciences Corporation.

Exact Sciences Corporation

A molecular diagnostics company headquartered in Madison, Wisconsin, known for its Cologuard colorectal cancer screening test.

Got photos? Submit your photos here. ›

The takeaway

The purchase of Exact Sciences shares by Bridgefront Capital LLC reflects ongoing institutional investor interest in the medical research company, which continues to expand its portfolio and market presence in the diagnostics space.